Edwards Lifesciences Corporation

Alpha Score of 43 reflects weak overall profile with strong momentum, poor value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Edwards Lifesciences Corporation is the leading global structural heart innovation company, specializing in patient-focused medical devices for structural heart disease, critical care, and surgical monitoring. The company develops and commercializes breakthrough technologies, including pioneering transcatheter aortic valve replacement (TAVR) systems and hemodynamic monitoring solutions, to address unmet needs in cardiovascular care through minimally invasive procedures. Its product portfolio encompasses heart valve therapies and monitoring systems that enhance patient outcomes and quality of life. Edwards Lifesciences Corporation collaborates with leading clinicians and researchers worldwide to deliver innovations in structural heart procedures, such as TAVR and mitral platforms, alongside critical care technologies. These offerings serve healthcare providers globally, emphasizing structural heart disease management and procedural efficiency. Founded in 2000 and headquartered in Irvine, California, Edwards Lifesciences Corporation plays a pivotal role in the medical device industry by advancing cardiovascular solutions and supporting clinical advancements in heart care.